Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast
Study Details
Study Description
Brief Summary
The standard treatment for participants whose cancer has returned after breast conserving surgery is radiation given twice daily (separated by at least 6 hours) for a total of 30 treatments. The purpose of this study is to find out if giving radiation once a day for 15 treatments after repeat breast conserving surgery works as well as giving it the standard way.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Breast cancer survival rates have greatly improved with advances in both screening and treatment. The standard of care for both early stage and selected locally advanced breast cancers is breast conserving therapy (BCT), consisting of a partial mastectomy followed by radiation treatment. Traditionally, a salvage mastectomy was the standard treatment for women who initially underwent BCT and experienced an ipsilateral breast tumor recurrence (IBTR). Many participants have become increasingly motivated to avoid mastectomy, and there has been rising interest in repeat BCS (Breast Conserving Surgery) with focal radiation for certain participants motivated to keep their breast. The current standard of care for breast re-irradiation after an in-breast tumor recurrence is partial breast irradiation consisting of a dose of 45 Gy delivered BID for 30 fractions. While this regimen demonstrated excellent local control and low AEs, the regimen itself is difficult for participants. Receiving RT twice daily at smaller doses per fraction (1.5 Gy) for 30 treatments can be burdensome, especially for those without reliable transportation or difficulty getting time away from work. Given the excellent local control rates and low rate of AEs, in this study, we hypothesize that daily hypofractionated EBRT(External Beam Radiation Therapy) for re-irradiation after repeat BCS would be at least as well tolerated with good local control and provide a more convenient option for participants than the current standard of care established by RTOG 1014. Some participants will present with high-risk features (e.g. age <50, high grade, ER negative tumors, close margins) making dose escalation an attractive option to improve local control. Options for dose escalation include sequential and concurrent administration of a boost.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Radiation Therapy(RT) There will be one treatment cohort. Radiation therapy will be delivered daily for 15 daily fractions, 2.67Gy per fraction, delivered using a 3-D or IMRT(Intensity Modulate Radiation Therapy) plan. For participants with high-risk features deemed by the radiation oncologist who would otherwise be a candidate for a boost (age <50, high grade, poor biology, close margins), 48 Gy delivered in fifteen fractions of 3.2 Gy is allowed. |
Radiation: Radiation Therapy
Weeks 1, 2 and 3
Weeks 1, 2 and 3 will include 5 days of treatment.
One radiation treatment to breast on each of the 5 days. Each radiation treatment session will last a 30 minutes.
|
Outcome Measures
Primary Outcome Measures
- Treatment-related adverse events as graded by CTCAE criteria [1 year from the completion of re-irradiation]
Rate of grade 3+ treatment-related skin, fibrosis, and breast pain adverse events occurring within 1 year from the completion of re-irradiation as graded by CTCAE criteria.
Secondary Outcome Measures
- In-breast tumor recurrence rate [3 years]
The overall in-breast tumor recurrence rate will be estimated using the cumulative incidence function.
- In-breast tumor recurrence rate [5 years]
The overall in-breast tumor recurrence rate is estimated using the cumulative incidence function.
- In-breast tumor recurrence rate [10 years]
The overall in-breast tumor recurrence rate will be estimated using the cumulative incidence function.
- Rate of freedom from mastectomy [3 years]
The freedom from mastectomy rate will be estimated using the cumulative incidence function.
- Rate of freedom from mastectomy [5 years]
The freedom from mastectomy rate will be estimated using the cumulative incidence function.
- Rate of freedom from mastectomy [10 years]
The freedom from mastectomy rate will be estimated using the cumulative incidence function.
- Treatment-related adverse events [1 year from completion of re-irradiation]
All treatment-related adverse events for the defined time periods
- Treatment-related adverse events [Overall for 3 years from completion of re-irradiation]
All treatment-related adverse events for the defined time periods
- Evaluation of Cosmesis [1 year]
Determined by an established Global Cosmesis Score grading from 1 through 4, with 1 being excellent and 4 being rated as poor
- Evaluation of Cosmesis [3 years]
Determined by an established Global Cosmesis Score grading from 1 through 4, with 1 being excellent and 4 being rated as poor
- Overall survival rate [3 years]
Overall survival will be estimated using Kaplan-Meier Method
- Overall survival rate [5 years]
Overall survival will be estimated using Kaplan-Meier Method
- Overall survival rate [10 years]
Overall survival will be estimated using Kaplan-Meier Method
- Mastectomy-free survival rate [3 years]
Mastectomy-free survival will be estimated using Kaplan-Meier Method
- Mastectomy-free survival rate [5 years]
Mastectomy-free survival will be estimated using Kaplan-Meier Method
- Mastectomy-free survival rate [10 years]
Mastectomy-free survival will be estimated using Kaplan-Meier Method
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants' recurrences must have histologically confirmed ductal carcinoma in-situ, invasive ductal, medullary, papillary, colloid (mucinous), or tubular histologies.
-
Lesion size < 3 cm treated with a partial mastectomy. Participants with clinically and radiographically negative axillas do not require an axillary lymph node sampling unless they did not have prior axillary lymph node sampling (e.g. previous cancer was DCIS). Repeat sentinel lymph node biopsy is permitted.
-
Unifocal breast cancer recurrence.
-
Negative resection margins with at least a no tumor on ink from invasive and 2 mm margins for ductal carcinoma in-situ or a negative re-excision.
-
Hormonal therapy is allowed. If chemotherapy is planned, the radiation is delivered first and chemotherapy must begin no earlier than two weeks following completion of radiation.
-
Participants must be > 18 years of age. Because no dosing or adverse event data are currently available on the use of breast re-irradiation in participants ≤18 years of age, children are excluded from this study.
-
Participants must have the ability to understand and the willingness to sign a written informed consent document.
-
Performance status: ECOG Performance status ≤ 2.
-
Life expectancy of ≥ 12months, in the opinion of and as documented by the investigator.
-
Not based on gender; this trial is open to any gender, defined as self-representation of gender identity.
Exclusion Criteria:
-
Participants with nodal or distant metastatic disease
-
Participants with invasive lobular carcinoma, extensive lobular carcinoma in-situ, extensive ductal carcinoma in-situ (spanning more than 3 cm), or uncontrolled nonepithelial breast malignancies such as lymphoma or sarcoma.
-
Participants with multicentric carcinoma (tumors in different quadrants of the breast or tumors separated by at least 4 cm). Palpable or radiographically suspicious contralateral axillary, ipsilateral or contralateral supraclavicular, infraclavicular, or internal mammary lymph nodes unless these are histologically or cytologically confirmed negative.
-
Extensive intraductal component (EIC) by the Harvard definition, i.e. 1) more than 25% of the invasive tumor is DCIS and DCIS present in adjacent breast tissue. Presence of an EIC increases the chance of local recurrence, and as such, one might not be a candidate for repeat breast conservation.
-
Participants with Paget's disease of the nipple.
-
Participants with skin involvement.
-
Participants with systemic lupus erythematosus requiring pharmacologic management, scleroderma, or dermatomyositis.
-
Participants with psychiatric, neurologic, or addictive disorders that would preclude obtaining informed consent.
-
Participants who are pregnant or lactating due to potential fetal exposure to radiation and unknown effects of radiation on lactating females.
-
Participants with known BRCA 1/BRCA 2 mutations.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center | Cleveland | Ohio | United States | 44106-5065 |
Sponsors and Collaborators
- Case Comprehensive Cancer Center
Investigators
- Principal Investigator: Janice Lyons, MD, University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CASE4123